- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) evaluated by blinded independent central review (BICR)
Inclusion criteria
- High- or very-high risk, localized or locally advanced prostate cancer